Selegiline (Anipryl / L-deprenyl) for Canine Cognitive Dysfunction

Bottom line

Selegiline (L-deprenyl; brand Anipryl) is an irreversible, selective MAO-B inhibitor dosed at 0.5–1.0 mg/kg PO once daily, preferably in the morning, and titrated to response [1]. Its benefit in canine cognitive dysfunction syndrome (CDS) is genuine but modest and largely owner-rated: the pivotal placebo-controlled field study showed improvement over placebo in sleep patterns, house-training, and activity within about four weeks [1], while a 641-dog open-label series reported 77.2% overall improvement by day 60 [2]. Selegiline is the only FDA-approved drug for CDS [3], which is itself a diagnosis of exclusion. The prescribing line you cannot cross is the serotonin-syndrome risk when selegiline meets other serotonergics — SSRIs, TCAs, trazodone, tramadol, or the amitraz in a tick collar — so plan washouts deliberately.

Drug facts

• Agent and class: selegiline hydrochloride (L-deprenyl), a phenethylamine-derived, selective monoamine oxidase type B (MAO-B) inhibitor. The Anipryl label describes it as "an irreversible inhibitor of monoamine oxidase" acting as "a selective inhibitor of MAO-B at recommended dosages in the dog," reflecting its greater affinity for the type-B active site [1].
• FDA-approved indications: Anipryl (selegiline hydrochloride; Zoetis) is labeled for control of clinical signs of canine cognitive dysfunction syndrome (CDS) and of uncomplicated canine pituitary-dependent hyperadrenocorticism (PDH) [1]; it is the only FDA-approved drug for CDS [3].
• Dose: 0.5–1.0 mg/kg PO q24h, given in the morning, rounded to the nearest whole tablet, then adjusted to response and tolerance [1].
• Mechanism: irreversible MAO-B inhibition enhances dopaminergic transmission — increasing dopamine synthesis and release while decreasing reuptake [4]. Selegiline is also reported to increase free-radical removal and reduce neurotoxicity by decreasing free-radical production, the putative neuroprotective/antioxidant effect that is frequently cited but less firmly established than its dopaminergic action [4].
• Onset: gradual; per VCA, incremental improvement is often noticeable within the first few days to a few weeks, but the full effect can take longer [5].

Efficacy in canine cognitive dysfunction

Set expectations honestly: the effect is real, owner-assessed, and — apart from the registration trial — uncontrolled. The FDA registration field study was placebo-controlled and showed that, after four weeks, Anipryl-treated dogs improved significantly versus placebo in sleep patterns, house-training, and activity level, with some dogs continuing to gain up to three months [1]. The largest clinical dataset is a non-comparative, open-label study of 641 dogs treated at 0.5–1.0 mg/kg once daily for 60 days: 77.2% showed overall improvement, and response by individual sign ranged from 67.8% (activity or sleep/wake cycle) to 77.8% (disorientation and interaction with family members) [2]. An earlier open-label series of 69 dogs aged 7–19 years given 0.5 mg/kg reported improvement in 77% at one month, 76% at two months, and 78% at three months [4].

The practical read: most treated dogs improve on at least one DISHAA domain, effect sizes are modest, the open-label figures carry placebo and observer bias, and true non-responders exist. A two-month therapeutic trial with dose titration is a reasonable test before abandoning the drug.

Adverse effects

Selegiline is generally well tolerated, with gastrointestinal and CNS-stimulatory signs predominating. In the 641-dog open-label study the most frequent adverse events were diarrhea (4.2%), anorexia (3.6%), and vomiting/salivation (3.4%) [2]. Reported reactions also include vomiting, restlessness or hyperactivity, disorientation, repetitive behaviors, and drooling, plus two that warrant prompt reassessment: diminished hearing/deafness and excessive panting [5]. In the registration field trial, 18 dogs (about 4%) had adverse events leading to discontinuation, dose reduction, or study dismissal — among them restlessness/agitation, vomiting, disorientation, diarrhea, and diminished hearing [1]. Because these are geriatric patients, separate a drug effect from progressive disease or comorbidity whenever new signs emerge.

Contraindications and drug interactions

This is the load-bearing safety section. Because selegiline is an MAO inhibitor, combining it with serotonergic or MAO-active drugs risks serotonin syndrome (agitation, hyperthermia, tremor, myoclonus, tachypnea, seizures).

• SSRIs and TCAs: the label directs clinicians to avoid combining Anipryl with selective serotonin reuptake inhibitors such as fluoxetine and with tricyclics such as clomipramine, amitriptyline, and imipramine, or other antidepressants [1]. This is precisely why the fluoxetine and clomipramine hubs sit on the same shelf as this one.
• Washouts — cite exactly, never improvise: "At least 14 days should elapse between discontinuation of Anipryl and initiation of treatment with a tricyclic antidepressant or selective serotonin reuptake inhibitor," and because of fluoxetine's long-lived active metabolite, "at least 5 weeks should elapse between discontinuation of fluoxetine and initiation of treatment with Anipryl" [1].
• Other MAOIs and serotonergics: concurrent use of selegiline with other MAOIs (e.g., amitraz) or serotonergic drugs (e.g., SSRIs, tramadol, trazodone) is contraindicated because of the increased serotonin-syndrome risk [3]. The amitraz caution is clinically live for tick-collar and demodicosis cases; the trazodone interaction is easy to miss because trazodone is otherwise a go-to sedative.
• Sympathomimetics: the label also states that "concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended" [1]; VCA extends the caution to phenylpropanolamine and bupropion [5], and the Anipryl label warns that concurrent MAO-inhibitor and alpha-2 agonist use can cause extreme blood-pressure swings, so blood-pressure monitoring is recommended [1].
• Opioids: "In humans, selegiline is contraindicated for use with meperidine, and this contraindication is often extended to other opioids" [1].

Dosing and monitoring

Start at the labeled 0.5–1.0 mg/kg PO once daily in the morning, rounded to the nearest whole tablet, then titrate to response and tolerance [1]. Before starting — and this is non-negotiable — treat CDS as a diagnosis of exclusion: rule out the medical mimics of "senility," including pain, metabolic disorders, organ failure, intracranial neoplasia, endocrinopathies, gastrointestinal and dermatologic disease, and sensory (visual/auditory) decline, using history, physical/neurologic/ophthalmologic examination, and bloodwork [6]. Frame baseline and follow-up around the DISHAA construct — Disorientation, altered social Interactions, Sleep–wake disruption, House-soiling, Activity change, and Anxiety/Aggression — so that response is tracked against defined signs [6]. Reassess for efficacy and adverse effects over a roughly 4–8 week window; if there is no benefit after about two months at an adequate dose, revisit the diagnosis or transition to alternatives [5].

Alternatives and adjuncts

Selegiline is one lever, and multimodal management outperforms any single drug. Evidence-supported adjuncts include therapeutic nutrition and supplements: an antioxidant-enriched senior diet (e.g., Hill's Prescription Diet b/d), medium-chain-triglyceride diets such as Purina Bright Mind (5.5% MCTs) or NeuroCare that supply ketone bodies as an alternative brain fuel, SAMe (e.g., Novifit), and combination antioxidant products such as Senilife (Ginkgo biloba, phosphatidylserine, vitamin E, resveratrol, pyridoxine) and Aktivait [4]. Environmental enrichment and regular exercise are neuroprotective and should be prescribed alongside any drug [4]. When anxiety dominates the picture, or selegiline is not tolerated, an SSRI or TCA may be substituted [4] — but only after the washout above [1], never as an overlap.

Frequently Asked Questions

What is the selegiline dose for canine cognitive dysfunction?

The FDA-approved Anipryl (selegiline) label specifies 0.5–1.0 mg/kg PO once daily, preferably in the morning, rounded to the nearest whole tablet and then titrated to response and tolerance.

How long until selegiline works in a dog with CDS?

Onset is gradual. VCA notes that improvement is often noticeable within the first few days to a few weeks, though the full effect can take longer; the Anipryl label's field study showed some dogs still improving out to three months, so allow roughly a two-month trial before judging response.

Can selegiline be combined with fluoxetine or trazodone?

No — this is the drug's headline safety issue. Clinician's Brief states that concurrent use of selegiline with other MAOIs (e.g., amitraz) or serotonergic drugs (e.g., SSRIs such as fluoxetine, tramadol, trazodone) is contraindicated because of the risk for serotonin syndrome. The Anipryl label adds specific washouts: at least 14 days off Anipryl before starting an SSRI or TCA, and at least 5 weeks off fluoxetine before starting Anipryl.

What is selegiline's mechanism of action in canine cognitive dysfunction?

It is an irreversible, selective MAO-B inhibitor; the Anipryl label notes it selectively inhibits MAO-B at canine therapeutic doses. As reviewed in Today's Veterinary Practice, this enhances dopaminergic transmission (increased dopamine synthesis and release, decreased reuptake) and is proposed to increase free-radical removal and reduce neurotoxicity.

Is Anipryl FDA-approved for canine cognitive dysfunction?

Yes. The DailyMed label shows it is approved for control of clinical signs of canine cognitive dysfunction syndrome (and uncomplicated pituitary-dependent hyperadrenocorticism), and Clinician's Brief notes it is the only FDA-approved drug for CDS.

What are selegiline's most common side effects?

In the 641-dog open-label study (Vet Ther, 2001) the most frequent adverse events were diarrhea (4.2%), anorexia (3.6%), and vomiting/salivation (3.4%); the Anipryl label and VCA also list restlessness and disorientation, plus diminished hearing and excessive panting as reactions warranting prompt review.

Does selegiline cure or reverse canine dementia?

No; it is symptomatic control, not a cure. The Anipryl registration field study showed improvement versus placebo in sleep, house-training, and activity at four weeks, and the 641-dog open-label study reported 77.2% owner-rated improvement by day 60 — but CDS is progressive, so pair the drug with diet, antioxidants, and enrichment.

Do I need to rule out other diseases before diagnosing CDS?

Yes. CDS is a diagnosis of exclusion. As emphasized in a 2025 narrative review (Veterinary Sciences), rule out pain, metabolic and endocrine disease, organ failure, intracranial neoplasia, and sensory decline with examination and bloodwork before attributing signs to cognitive dysfunction.